Valrubicin

Valrubicin (val-ROO-bih-sin)A drug used to treat bladder carcinoma in situ that did not get better after treatment with bacillus Calmette-Guerin (BCG). It is used in patients who cannot have surgery right away to remove all or part of the bladder. Valrubicin is given as a solution through a catheter that is placed into the bladder. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Valrubicin is a type of anthracycline antibiotic and a type of topoisomerase inhibitor. Also called AD 32 and Valstar.

Information about Valrubicin

Valrubicin is a synthetic analogue of doxorubicin that is used to treat refractory urinary bladder cancer.

Clinical use of Valrubicin

Valrubicin has been shown to induce clinical remissions in 18% to 30% of patients. It was approved as a therapy of bladder cancer in the United States 1998, was removed in 2002 because of manufacturing issues, but reintroduced in 2009.

Dosage and administration for Valrubicin

Valrubicin is available only for intravesicular use in 5 mL single dose vials of 200 mg under the brand name Valstar. The recommended dose is 800 mg instilled in the bladder once weekly for 6 weeks.

Side effects of Valrubicin

Common side effects include bladder pain and irritation, urgency and dysuria. Systemic absorption is minimal and systemic side effects are uncommon.

The article on Valrubicin is a stub. YOU can help Wikimd by expanding it!

Medication resources

WikiMD is a sponsored by W8MD Weight loss, sleep and medical aesthetics.

Learn more

• Dailymed label info
• Scientific articles

WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Help WikiMD: Find something you can improve? Join WikiMD as an an editor and help improve the page Valrubicin or others.